NYSE · INSP
Inspire Medical Systems, Inc.
Healthcare · Medical - Devices
$68.10▼ 4.33% ($3.08)at close
As of 4:00 PM ET
Market cap
$1.97B
P/E
14.59
EPS (TTM)
$4.67
Next earnings
Nov 2, 2026
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 18.3% revenue growth a year for 10 years. Our scenarios assume 9.4–16.3%.
That's below its past 4-year pace of 40.6%.
Value per share
Base case
$50.07
Price used $68.10 is 36% above this
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
Revenue each value needs
Revenue today $899M. The price needs $4.8B by 2036. Base case: $3.1B. At its recent pace: $27.1B. Bear to Bull: $2.2B to $4.1B.
Revenue today $899M. The price needs $4.8B by 2036. Base case: $3.1B. At its recent pace: $27.1B. Bear to Bull: $2.2B to $4.1B.
Revenue in 2036
today $899M
+$1.8Bmore than the Base case · 1.6×
Value per share · Base case
$50.07
Price $68.10
36% above this
- 10-yr revenue CAGR
- 13.1%
- Ending operating margin
- 7.2%
- Discount rate
- 8.0%
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 6.8% over the last year. Revenue grew 4.35% over the trailing twelve months. Operating margin moved from 4.81% to 6.02%. Free cash flow grew 37.74% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 6.02%. A decisive move in revenue — currently up 4.35% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
12
Buy
16
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 2, 2026
Q3 FY26 · EPS est $0.09 · Revenue est $204.3M
Same quarter, year over year
FY26 YTD -56.4%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $0.24 vs $0.55 · 0 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $2.58
- +49.1%
- FY24
- $1.73
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q2 FY26
Reported Aug 3, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.14
Estimate
-$0.24
Year over year
-68.9%
Vs prior quarter
+40.0%
Institutional Sentiment
Inspire Medical Systems, Inc. · INSP
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.